Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

March 18, 2025

Health Canada approves Arcutis’ roflumilast cream 0.15% for atopic dermatitis

Health Canada has granted approval for Arcutis’ topical formulation Zoryve (roflumilast cream 0.15%) for mild to moderate atopic dermatitis (AD) treatment in adults and paediatrics aged six years and above.

Health Canada approves Arcutis’ roflumilast cream 0.15% for atopic dermatitis